Istituto Di Candiolo Fondazione Del Piemonte Per Loncologia IRCCS

At Istituto Di Candiolo Fondazione Del Piemonte Per Loncologia IRCCS, a large share of the clinical trial program focuses on cancer across a wide range of solid tumors. The studies are designed to test new treatment combinations, compare them with current standard care, and improve outcomes for patients with advanced or hard-to-treat disease.

• Advanced and metastatic breast cancer, including hormone receptor-positive disease
• Non-small cell lung cancer and other advanced thoracic cancers
• Prostate cancer, including localized, metastatic, and hormone-sensitive forms
• Endometrial cancer and other recurrent gynecologic malignancies
• Testing targeted therapies, immunotherapy combinations, and better treatment strategies

These trials aim to improve disease control, slow progression, and expand options for people with limited standard treatments.

The site also has a strong research portfolio in hematologic cancers, especially lymphoma and multiple myeloma. The studies explore new immune-based therapies and combination approaches intended to deepen responses and help patients whose disease has returned or no longer responds well to prior treatment.

• Follicular lymphoma and marginal zone lymphoma
• Diffuse large B-cell lymphoma and other aggressive lymphomas
• Relapsed/refractory multiple myeloma
• Evaluating new antibody-based therapies and treatment combinations
• Comparing novel regimens with established chemotherapy or immunotherapy approaches

These investigations are aimed at improving response rates, prolonging remission, and offering more effective options for patients with difficult blood cancers.

Clinical research at this hospital/clinic includes a notable emphasis on precision medicine, where treatment is matched to specific tumor features such as genetic alterations or receptor status. This approach is helping the team study whether targeted therapies can deliver better control in selected patient groups.

• KRAS G12C-mutated solid tumors and lung cancer
• HER2-positive and HER2-mutant cancers
• MET-amplified non-squamous lung cancer
• ER-positive/HER2-negative breast cancer
• Using biomarker-driven studies to refine treatment selection

These trials are focused on identifying which targeted therapies are most effective for specific tumor subtypes and on improving the match between patient and treatment.

Some trials at Istituto Di Candiolo Fondazione Del Piemonte Per Loncologia IRCCS examine how local treatments can be combined with systemic therapy to improve cure rates or delay recurrence. This includes research around surgery, radiation, and treatment given before or after the main intervention.

• Colorectal cancer and other resectable tumors
• Sarcoma, including retroperitoneal subtypes
• Prostate cancer treated with radiation-based strategies
• Testing whether adding radiation or preoperative therapy improves outcomes
• Assessing whether local treatment can better control limited metastatic disease

These studies aim to strengthen treatment effectiveness around the time of surgery or radiotherapy and to improve long-term disease control.